| Target | Clinical trial | Disease | Primary outcome |
---|---|---|---|---|
PF-04620110 | DGAT1 | Phase I NCT01064492 | 12 healthy volunteers | Â |
 |  | Phase IB NCT01298518 | 48 type 2 diabetes mellitus subjects | Reduced postprandial TG excursions [159] |
AZD7687 | DGAT1 | Phase I NCT01046357 | 80 healthy male subjects | Decreased postprandial TG excursions approximately 75% compared to placebo following a fat containing meal (p < 0.0001) [160] |
Pradigastat (LCQ-908) | DGAT1 | Phase I [172] | Overweight or obese healthy subjects (single-dose cohorts, n = 72) (multiple-dose cohorts, n = 106) | Pradigastat treatment (single and multiple doses) led to dose-dependent suppression of postprandial triglyceride excursions over 9 h following a high-fat meal test. Pradigastat was safe and tolerated at single and multiple doses in healthy subjects |
 |  | Phase III NCT01514461 | 45 adults with familial chylomicronemia syndrome (FCS) (Hyperlipoproteinemia type I) | Reduced both postprandial and fasting triglycerides from baseline to 12 weeks after treatment (fasting TG: LCQ908 vs placebo: − 13.9 vs 45.6, p = 0.0182) |
Ervogastat (PF-06865571) | DGAT2 | Phase I NCT04044053 | 12 healthy adult participants | Â |
 |  | Phase I NCT03092232 | 17 healthy adult participants |  |
 |  | Phase I NCT03230383 | 60 healthy adults including overweight and obese |  |
 |  | Phase I NCT03513588 | 48 people with nonalcoholic fatty liver disease | Relative change from baseline in whole liver fat at Day 15 after treatment (PF-06865571 300 mg vs placebo: − 41.14 vs − 10.94, p < 0.001) |
 |  | Phase II NCT04399538 | 75 adult participants with presumed nonalcoholic steatohepatitis | DGAT2i combined with ACC inhibitors significantly reduced percentage of liver fat after 6 weeks treatment compared to placebo (− 58.80% vs − 3.58, p < 0.001) |
 |  | Phase II NCT04321031 | 450 non-alcoholic steatohepatitis with fibrosis |  |